Celgene’s Alkeran Extends Life in Eye-Cancer Patients in Study
Stock Chart for Celgene Corp (CELG)
Melphalan, the active ingredient in Celgene Corp. (CELG)’s Alkeran, helped patients live longer after cancer had spread from their eyes to their livers, according to a study to be presented today at the European Multidisciplinary Cancer Congress in Stockholm.
To contact the reporter on this story: Kristen Hallam in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.